U.S. markets closed

Sophiris Bio, Inc. (SPHS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0310+0.0050 (+19.23%)
At close: 3:54PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0260
Open0.0256
Bid0.0000 x 2200
Ask0.0000 x 800
Day's Range0.0250 - 0.0329
52 Week Range0.0100 - 0.7200
Volume225,405
Avg. Volume501,118
Market Cap1.069M
Beta (5Y Monthly)1.36
PE Ratio (TTM)31.00
EPS (TTM)0.0010
Earnings DateNov 09, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Sophiris Bio To Shut Down Operations
    PR Newswire

    Sophiris Bio To Shut Down Operations

    Sophiris Bio Inc. (OTCQB: SPHS) (the "Company" or "Sophiris"), today announced that its board of directors has formally approved an immediate shutdown of the operations of the Company. The Company has been unable to find a partner or raise capital to support the continued development of topsalysin in either benign prostatic hyperplasia or localized prostate cancer.

  • GlobeNewswire

    Sophiris Bio Announces Nasdaq Delisting

    Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that on March 10, 2020, the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (“Panel”) had determined to delist the Company’s shares from The Nasdaq Stock Market LLC (“Nasdaq”), and that trading in the Company’s common shares will be suspended effective at the open of business on March 12, 2020. Nasdaq will thereafter file a Form 25 with the Securities and Exchange Commission (“SEC”) to effect the formal delisting of the Company’s common stock following the expiration of all applicable Nasdaq procedures.